NO20091283L - Humane antistoffer som binder CXCR4 og anvendelser derav - Google Patents
Humane antistoffer som binder CXCR4 og anvendelser deravInfo
- Publication number
- NO20091283L NO20091283L NO20091283A NO20091283A NO20091283L NO 20091283 L NO20091283 L NO 20091283L NO 20091283 A NO20091283 A NO 20091283A NO 20091283 A NO20091283 A NO 20091283A NO 20091283 L NO20091283 L NO 20091283L
- Authority
- NO
- Norway
- Prior art keywords
- antibodies
- present disclosure
- cxcr4
- methods
- applications
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
SAMMENDRAG Foreliggende beskrivelse tilveiebringer isolerte monoklonale antistoffer som spesifikt binder til CXCR4 med høy affinitet, særlig humane monoklonale antistoffer. Nukleinsyre molekyler som koder antistoffene i følge foreliggende beskrivelse, ekspresjonsvektorer, vertsceller og fremgangsmåter for å uttrykke antistoffene i følge foreliggende beskrivelse er også tilveiebrakt. Immunokonjugater, bispesifikke molekyler og farmasøytiske sammensetninger som innbefatter antistoffene i følge foreliggende beskrivelse er også tilveiebrakt. Foreliggende beskrivelse tilveiebringer også fremgangsmåter for detektering av CXCR4, så vel som fremgangsmåter for behandling av forskjellige kreftformer, inflammatoriske forstyrrelser og HIV infeksjon ved anvendelse av et anti-CXCR4 antistoff i følge foreliggende beskrivelse.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82785106P | 2006-10-02 | 2006-10-02 | |
PCT/US2007/021152 WO2008060367A2 (en) | 2006-10-02 | 2007-10-01 | Human antibodies that bind cxcr4 and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20091283L true NO20091283L (no) | 2009-04-24 |
NO345287B1 NO345287B1 (no) | 2020-11-30 |
Family
ID=39402166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20091283A NO345287B1 (no) | 2006-10-02 | 2009-03-30 | Humane antistoffer som binder CXCR4 og anvendelser derav |
Country Status (30)
Country | Link |
---|---|
US (3) | US8450464B2 (no) |
EP (2) | EP2066351B1 (no) |
JP (4) | JP5417175B2 (no) |
KR (3) | KR20150065959A (no) |
CN (2) | CN101528259B (no) |
AR (2) | AR063086A1 (no) |
AU (1) | AU2007320024B2 (no) |
BR (1) | BRPI0718197A2 (no) |
CA (1) | CA2665239A1 (no) |
CL (1) | CL2007002835A1 (no) |
CY (2) | CY1117036T1 (no) |
DK (2) | DK2486941T3 (no) |
EA (1) | EA018836B1 (no) |
ES (2) | ES2553553T3 (no) |
HK (1) | HK1131904A1 (no) |
HU (2) | HUE033630T2 (no) |
IL (1) | IL197831A (no) |
LT (1) | LT2486941T (no) |
ME (1) | ME02269B (no) |
MX (1) | MX2009003306A (no) |
NO (1) | NO345287B1 (no) |
NZ (1) | NZ575924A (no) |
PL (2) | PL2486941T3 (no) |
PT (2) | PT2066351E (no) |
RS (2) | RS55740B1 (no) |
SG (2) | SG178712A1 (no) |
SI (2) | SI2066351T1 (no) |
TW (2) | TWI522366B (no) |
WO (1) | WO2008060367A2 (no) |
ZA (1) | ZA200902256B (no) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008009437A2 (en) | 2006-07-18 | 2008-01-24 | Noxxon Pharma Ag | Sdf-i binding nucleic acids |
SI2066351T1 (sl) * | 2006-10-02 | 2016-02-29 | E.R. Squibb & Sons, L.L.C. | Humana protitelesa, ki vežejo cxcr4 in njihova uporaba |
FR2915102B1 (fr) * | 2007-04-23 | 2014-05-16 | Pf Medicament | Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer |
HUE047459T2 (hu) | 2007-08-06 | 2020-04-28 | Noxxon Pharma Ag | SDF-1 kötõ nukleinsavak és alkalmazásuk |
CA2724409A1 (en) * | 2008-05-14 | 2009-11-19 | Eli Lilly And Company | Anti-cxcr4 antibodies |
US7892546B2 (en) | 2008-05-14 | 2011-02-22 | Eli Lilly And Company | Anti-CXCR4 antibodies |
CN102459575A (zh) | 2009-06-05 | 2012-05-16 | 细胞动力国际有限公司 | 重编程t细胞和造血细胞的方法 |
US20110117113A1 (en) * | 2009-10-09 | 2011-05-19 | Gerald Beste | Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them |
LT2499161T (lt) * | 2009-11-11 | 2017-11-27 | Ganymed Pharmaceuticals Gmbh | Specifiniai antikūnai, skirti klaudinui 6 (cldn6) |
WO2011083141A2 (en) * | 2010-01-08 | 2011-07-14 | Ablynx Nv | Method for generation of immunoglobulin sequences by using lipoprotein particles |
GB201002238D0 (en) | 2010-02-10 | 2010-03-31 | Affitech As | Antibodies |
EP2371863A1 (en) * | 2010-03-30 | 2011-10-05 | Pierre Fabre Médicament | Humanized anti CXCR4 antibodies for the treatment of cancer |
WO2011161266A1 (en) * | 2010-06-25 | 2011-12-29 | Ablynx Nv | Improved immunoglobulin single variable domains and constructs thereof directed against cxcr4 |
US20140120555A1 (en) * | 2011-06-20 | 2014-05-01 | Pierre Fabre Medicament | Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer |
ES2758884T3 (es) | 2011-06-24 | 2020-05-06 | Stephen D Gillies | Proteínas de fusión de inmunoglobulina a través de cadena ligera y métodos de uso de ellas |
CA2840687C (en) | 2011-07-01 | 2020-04-28 | Dana-Farber Cancer Institute, Inc. | Discovery of a somatic mutation in myd88 gene in lymphoplasmacytic lymphoma |
US20140314784A1 (en) * | 2011-07-20 | 2014-10-23 | Medlmmune Limited | Anti-cxcr4 antibodies and methods of use |
AR087363A1 (es) * | 2011-07-29 | 2014-03-19 | Pf Medicament | Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres |
AR087364A1 (es) | 2011-07-29 | 2014-03-19 | Pf Medicament | Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres |
SI2776032T1 (sl) * | 2011-11-09 | 2018-12-31 | Bristol-Myers Squibb Company | Zdravljenje hematoloških malignih obolenj z anti-CXCR4 protitelesom |
CA2891493C (en) * | 2013-02-26 | 2022-03-15 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
JP6636917B2 (ja) | 2013-06-28 | 2020-01-29 | エックス−ボディ インコーポレイテッド | 標的細胞に特異的な標的エピトープの同定のための、標的抗原探索、表現型スクリーニングおよびそれらの使用 |
MX371455B (es) * | 2013-08-02 | 2020-01-28 | Pfizer | Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco. |
WO2015019284A2 (en) * | 2013-08-05 | 2015-02-12 | Cambridge Enterprise Limited | Inhibition of cxcr4 signaling in cancer immunotherapy |
WO2015038887A1 (en) * | 2013-09-12 | 2015-03-19 | Dana-Farber Cancer Institute Inc. | Methods for evaluating and treating waldenstrom's macroglobulinemia |
CN110058023B (zh) * | 2013-09-23 | 2022-10-14 | X博迪公司 | 用于生成对抗细胞表面抗原的结合剂的方法和组合物 |
ES2742079T3 (es) | 2013-11-06 | 2020-02-13 | Bristol Myers Squibb Co | Tratamiento de macroglobulinemia de Waldenström asociada a C1013G/CXCR4 con un anticuerpo anti-CXCR4 |
WO2015085075A1 (en) | 2013-12-06 | 2015-06-11 | Dana-Farber Cancer Institute, Inc. | Methods to distinguish waldenström's macroglobulinemia from igm monoclonal gammopathy of undetermined significance |
US20160340414A1 (en) | 2014-01-15 | 2016-11-24 | Medimmune, Llc | Rsv-specific antibodies and functional parts thereof |
JP2017527615A (ja) * | 2014-09-02 | 2017-09-21 | シーダーズ−サイナイ メディカル センター | 線維化疾患及び癌を治療するための組成物及び方法 |
WO2016081455A1 (en) * | 2014-11-17 | 2016-05-26 | Pelican Therapeutics, Inc. | Human tnfrsf25 antibody |
SG10202111844VA (en) * | 2015-01-09 | 2021-12-30 | Adalta Ltd | Cxcr4 binding molecules |
ES2747386T3 (es) | 2015-01-14 | 2020-03-10 | Bristol Myers Squibb Co | Dímeros de benzodiacepina unidos por heteroarileno, conjugados de los mismos y métodos de preparación y uso |
RU2719033C2 (ru) | 2015-04-23 | 2020-04-16 | Нантомикс, Ллс | Способ получения фармацевтического агента для иммунотерапии рака |
MX2017015811A (es) * | 2015-06-12 | 2018-04-10 | Squibb Bristol Myers Co | Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4). |
EP3394096A1 (en) | 2015-12-21 | 2018-10-31 | Bristol-Myers Squibb Company | Variant antibodies for site-specific conjugation |
EP3448390A1 (en) | 2016-04-29 | 2019-03-06 | Dana-Farber Cancer Institute, Inc. | Hck as a therapeutic target in myd88 mutated diseases |
EP3454909A1 (en) | 2016-05-10 | 2019-03-20 | Bristol-Myers Squibb Company | Antibody-drug conjugates of tubulysin analogs with enhanced stability |
US10005843B2 (en) | 2016-06-09 | 2018-06-26 | Pelican Therapeutics, Inc. | Anti-TNFRSF25 antibodies |
WO2017220989A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
KR102493853B1 (ko) | 2016-08-19 | 2023-01-30 | 브리스톨-마이어스 스큅 컴퍼니 | 세코-시클로프로파피롤로인돌 화합물, 그의 항체-약물 접합체, 및 제조 및 사용 방법 |
WO2018075842A1 (en) | 2016-10-20 | 2018-04-26 | Bristol-Myers Squibb Company | Condensed benzodiazepine derivatives and conjugates made therefrom |
CA3052070A1 (en) * | 2017-01-31 | 2018-08-09 | Msm Protein Technologies Inc. | Anti-cxcr4 antibodies |
US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
KR20200132915A (ko) * | 2018-03-13 | 2020-11-25 | 푼다시온 파라 라 인베스티가시온 바이오메디카 델 호스피탈 우니베르시타리오 라 파즈 | 암 면역요법을 위한, 활성화되고 확장된 자연 킬러 세포와 조합된 항-cxcr4 항체 |
US11485741B2 (en) | 2018-04-24 | 2022-11-01 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (TLR7) agonists |
EA202092747A1 (ru) | 2018-05-29 | 2021-03-16 | Бристол-Маерс Сквибб Компани | Модифицированные саморазрушающиеся фрагменты для применения в пролекарствах и конъюгатах и способы применения и изготовления |
US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
PL3886914T3 (pl) | 2018-11-30 | 2023-05-08 | Bristol-Myers Squibb Company | Przeciwciało zawierające c-końcowe rozszerzenie łańcucha lekkiego zawierające glutaminę, jego koniugaty oraz metody i zastosowania |
KR20210102334A (ko) | 2018-12-12 | 2021-08-19 | 브리스톨-마이어스 스큅 컴퍼니 | 트랜스글루타미나제 접합을 위해 변형된 항체, 그의 접합체, 및 방법 및 용도 |
WO2021055306A1 (en) | 2019-09-16 | 2021-03-25 | Bristol-Myers Squibb Company | Dual capture method for analysis of antibody-drug conjugates |
EP4051298A1 (en) | 2019-11-01 | 2022-09-07 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progentor cells |
AU2021205893A1 (en) | 2020-01-08 | 2022-06-23 | Synthis Therapeutics, Inc. | ALK5 inhibitor conjugates and uses thereof |
MX2022013493A (es) | 2020-04-27 | 2023-02-22 | Magenta Therapeutics Inc | Metodos y composiciones para transducir celulas madre y progenitoras hematopoyeticas in vivo. |
CN112661845B (zh) * | 2020-12-25 | 2022-06-21 | 暨南大学 | 与cxcr4结合的亲和力成熟结合蛋白及其应用 |
CN112521500B (zh) * | 2020-12-25 | 2022-06-24 | 暨南大学 | 与cxcr4结合的亲和力成熟结合蛋白及应用 |
WO2022197776A1 (en) | 2021-03-16 | 2022-09-22 | Magenta Therapeutics, Inc. | Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients |
CN117003876A (zh) * | 2023-08-31 | 2023-11-07 | 恺佧生物科技(上海)有限公司 | 一种Anti-CXCR4膜蛋白抗体及其制备方法和应用 |
Family Cites Families (153)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4954617A (en) | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
EP0623679B1 (en) | 1987-05-21 | 2003-06-25 | Micromet AG | Targeted multifunctional proteins |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
JP2989002B2 (ja) | 1988-12-22 | 1999-12-13 | キリン―アムジエン・インコーポレーテツド | 化学修飾顆粒球コロニー刺激因子 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US6261774B1 (en) | 1990-06-11 | 2001-07-17 | Gilead Sciences, Inc. | Truncation selex method |
US5712375A (en) | 1990-06-11 | 1998-01-27 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
US5864026A (en) | 1990-06-11 | 1999-01-26 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
US5763566A (en) | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue SELEX |
US5789157A (en) | 1990-06-11 | 1998-08-04 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
GB9021679D0 (en) * | 1990-10-05 | 1990-11-21 | Gorman Scott David | Antibody preparation |
GB9108652D0 (en) | 1991-04-23 | 1991-06-12 | Antisoma Ltd | Immunoreactive compounds |
JP3949712B2 (ja) | 1991-12-02 | 2007-07-25 | メディカル リサーチ カウンシル | 抗体セグメントレパートリー由来でファージに表示される抗自己抗体の産生 |
ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル,インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
CA2144043C (en) | 1992-09-16 | 2005-01-18 | Dennis R. Burton | Human neutralizing monoclonal antibodies to respiratory syncytial virus |
GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
JP3919830B2 (ja) | 1992-11-28 | 2007-05-30 | 財団法人化学及血清療法研究所 | 抗ネコヘルペスウイルス−1組換え抗体および該抗体をコードする遺伝子断片 |
EP0754225A4 (en) | 1993-04-26 | 2001-01-31 | Genpharm Int | HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS |
DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
JP3367581B2 (ja) | 1993-10-14 | 2003-01-14 | 小野薬品工業株式会社 | 新規なポリペプチド、その製造方法、そのポリペプチドをコードするdna、そのdnaからなるベクター、そのベクターで形質転換された宿主細胞 |
AU1866895A (en) | 1994-01-04 | 1995-08-01 | Scripps Research Institute, The | Human monoclonal antibodies to herpes simplex virus and methods therefor |
SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6013443A (en) | 1995-05-03 | 2000-01-11 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue SELEX |
WO1996034875A1 (en) | 1995-05-03 | 1996-11-07 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
US5840598A (en) | 1997-08-14 | 1998-11-24 | Micron Technology, Inc. | LOC semiconductor assembled with room temperature adhesive |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
EP2261229A3 (en) | 1998-04-20 | 2011-03-23 | GlycArt Biotechnology AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
GB9814383D0 (en) | 1998-07-02 | 1998-09-02 | Cambridge Antibody Tech | Improvements relating to antibodies |
WO2000005266A1 (en) | 1998-07-21 | 2000-02-03 | Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung Mbh | Anti hepatitis c virus antibody and uses thereof |
NZ539776A (en) | 1999-01-15 | 2006-12-22 | Genentech Inc | Polypeptide variants with altered effector function |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
EP2270148A3 (en) | 1999-04-09 | 2011-06-08 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
US6387620B1 (en) | 1999-07-28 | 2002-05-14 | Gilead Sciences, Inc. | Transcription-free selex |
CA2380813A1 (en) | 1999-07-29 | 2001-02-08 | Medarex, Inc. | Human monoclonal antibodies to her2/neu |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
KR100942863B1 (ko) | 1999-08-24 | 2010-02-17 | 메다렉스, 인코포레이티드 | 인간 씨티엘에이-4 항체 및 그의 용도 |
US6794132B2 (en) | 1999-10-02 | 2004-09-21 | Biosite, Inc. | Human antibodies |
ES2288886T3 (es) | 1999-12-30 | 2008-02-01 | Dana-Farber Cancer Institute, Inc. | Proteoliposomas que contienen una proteina integral de membrana que tiene uno o mas dominios transmembrana. |
US7417130B2 (en) | 2000-09-08 | 2008-08-26 | University Of Zurich | Collection of repeat proteins comprising repeat modules |
US7138496B2 (en) * | 2002-02-08 | 2006-11-21 | Genetastix Corporation | Human monoclonal antibodies against human CXCR4 |
US6818216B2 (en) | 2000-11-28 | 2004-11-16 | Medimmune, Inc. | Anti-RSV antibodies |
ES2295228T3 (es) | 2000-11-30 | 2008-04-16 | Medarex, Inc. | Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos. |
US20040001822A1 (en) | 2000-12-29 | 2004-01-01 | Avigdor Levanon | Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
AU2002256371B2 (en) | 2001-04-26 | 2008-01-10 | Amgen Mountain View Inc. | Combinatorial libraries of monomer domains |
US20050048512A1 (en) | 2001-04-26 | 2005-03-03 | Avidia Research Institute | Combinatorial libraries of monomer domains |
US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
US20040175756A1 (en) | 2001-04-26 | 2004-09-09 | Avidia Research Institute | Methods for using combinatorial libraries of monomer domains |
US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
KR100583331B1 (ko) | 2001-05-11 | 2006-05-26 | 기린 비루 가부시키가이샤 | 인간 항체 λ 경쇄 유전자를 포함하는 인간 인공 염색체 및 자손 전달 가능한 상기 인간 인공 염색체를 포함하는 비인간 동물 |
WO2002092780A2 (en) | 2001-05-17 | 2002-11-21 | Diversa Corporation | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof |
AU2002319402B2 (en) | 2001-06-28 | 2008-09-11 | Domantis Limited | Dual-specific ligand and its use |
HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
US7442512B2 (en) * | 2001-11-30 | 2008-10-28 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
PL373256A1 (en) | 2002-04-09 | 2005-08-22 | Kyowa Hakko Kogyo Co, Ltd. | Cells with modified genome |
CA2489280A1 (en) | 2002-06-14 | 2003-12-24 | Centocor, Inc. | Modified "s" antibodies |
JP2006512895A (ja) | 2002-06-28 | 2006-04-20 | ドマンティス リミテッド | リガンド |
DE10161767T1 (de) | 2002-07-03 | 2018-06-07 | Honjo Tasuku | Immunopotenzierende Zusammensetzungen, die einen Anti-PD-L1 Antikörper enthalten |
KR100944575B1 (ko) | 2002-10-17 | 2010-02-25 | 젠맵 에이/에스 | Cd20에 대한 인간 모노클로날 항체 |
EP2267032A3 (en) | 2002-11-08 | 2011-11-09 | Ablynx N.V. | Method of administering therapeutic polypeptides, and polypeptides therefor |
AU2003299581A1 (en) | 2002-12-02 | 2004-06-23 | Abgenix, Inc. | Antibodies against drugs of abuse |
US20050002939A1 (en) * | 2002-12-23 | 2005-01-06 | Albert Zlotnik | Tumor killing/tumor regression using CXCR4 antagonists |
AU2003290330A1 (en) | 2002-12-27 | 2004-07-22 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
US9259459B2 (en) | 2003-01-31 | 2016-02-16 | Celldex Therapeutics Inc. | Antibody vaccine conjugates and uses therefor |
US20090005257A1 (en) | 2003-05-14 | 2009-01-01 | Jespers Laurent S | Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire |
CA2526398C (en) | 2003-05-21 | 2014-07-15 | Medarex, Inc. | Human monoclonal antibodies against bacillus anthracis protective antigen |
PL1639011T3 (pl) | 2003-06-30 | 2009-05-29 | Domantis Ltd | Pegilowane przeciwciała jednodomenowe (dAb) |
HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
US7674618B2 (en) | 2003-09-04 | 2010-03-09 | Medarex, Inc. | Expression vector |
WO2005040229A2 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
US20050249723A1 (en) | 2003-12-22 | 2005-11-10 | Xencor, Inc. | Fc polypeptides with novel Fc ligand binding sites |
US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
CA2587424A1 (en) | 2004-11-16 | 2006-05-26 | Avidia Research Institute | Protein scaffolds and uses thereof |
AR051805A1 (es) * | 2004-12-21 | 2007-02-07 | Centocor Inc | Anticuerpos anti-il-12, epitopos, composiciones, metodos y usos |
JP2008528010A (ja) | 2005-01-31 | 2008-07-31 | アブリンクス ナームローゼ フェンノートシャップ | 重鎖抗体の可変ドメイン配列を作出する方法 |
KR101291640B1 (ko) | 2005-02-18 | 2013-08-05 | 메다렉스, 엘.엘.시. | 푸코실 잔기가 결핍된 전립선 특이적 막 항원(psma)에대한 단클론성 항체 |
US8329178B2 (en) * | 2005-02-18 | 2012-12-11 | Dana-Farber Cancer Institute, Inc. | Antibodies against CXCR4 and methods of use thereof |
WO2006096488A2 (en) | 2005-03-08 | 2006-09-14 | Pharmacia & Upjohn Company Llc | Composition comprising human igg2 antibody and chelating agent |
AU2006294644A1 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
SI2066351T1 (sl) * | 2006-10-02 | 2016-02-29 | E.R. Squibb & Sons, L.L.C. | Humana protitelesa, ki vežejo cxcr4 in njihova uporaba |
SI2776032T1 (sl) * | 2011-11-09 | 2018-12-31 | Bristol-Myers Squibb Company | Zdravljenje hematoloških malignih obolenj z anti-CXCR4 protitelesom |
ES2742079T3 (es) * | 2013-11-06 | 2020-02-13 | Bristol Myers Squibb Co | Tratamiento de macroglobulinemia de Waldenström asociada a C1013G/CXCR4 con un anticuerpo anti-CXCR4 |
-
2007
- 2007-10-01 SI SI200731704T patent/SI2066351T1/sl unknown
- 2007-10-01 DK DK12155398.6T patent/DK2486941T3/en active
- 2007-10-01 TW TW096136759A patent/TWI522366B/zh not_active IP Right Cessation
- 2007-10-01 CN CN200780040511.4A patent/CN101528259B/zh active Active
- 2007-10-01 TW TW104133865A patent/TWI592425B/zh not_active IP Right Cessation
- 2007-10-01 WO PCT/US2007/021152 patent/WO2008060367A2/en active Application Filing
- 2007-10-01 EP EP07867192.2A patent/EP2066351B1/en active Active
- 2007-10-01 SG SG2011071958A patent/SG178712A1/en unknown
- 2007-10-01 BR BRPI0718197-3A2A patent/BRPI0718197A2/pt not_active Application Discontinuation
- 2007-10-01 CN CN201410083654.5A patent/CN103897058B/zh active Active
- 2007-10-01 SI SI200731920T patent/SI2486941T1/sl unknown
- 2007-10-01 RS RS20170519A patent/RS55740B1/sr unknown
- 2007-10-01 NZ NZ575924A patent/NZ575924A/en unknown
- 2007-10-01 EP EP12155398.6A patent/EP2486941B1/en active Active
- 2007-10-01 ME MEP-2015-771A patent/ME02269B/me unknown
- 2007-10-01 ES ES07867192.2T patent/ES2553553T3/es active Active
- 2007-10-01 PT PT78671922T patent/PT2066351E/pt unknown
- 2007-10-01 PL PL12155398T patent/PL2486941T3/pl unknown
- 2007-10-01 RS RS20150771A patent/RS54424B1/en unknown
- 2007-10-01 KR KR1020157014573A patent/KR20150065959A/ko not_active Application Discontinuation
- 2007-10-01 HU HUE12155398A patent/HUE033630T2/en unknown
- 2007-10-01 SG SG10201608268RA patent/SG10201608268RA/en unknown
- 2007-10-01 CA CA002665239A patent/CA2665239A1/en not_active Abandoned
- 2007-10-01 ES ES12155398.6T patent/ES2625798T3/es active Active
- 2007-10-01 AR ARP070104347A patent/AR063086A1/es active IP Right Grant
- 2007-10-01 AU AU2007320024A patent/AU2007320024B2/en not_active Ceased
- 2007-10-01 JP JP2009531416A patent/JP5417175B2/ja active Active
- 2007-10-01 DK DK07867192.2T patent/DK2066351T3/en active
- 2007-10-01 PL PL07867192T patent/PL2066351T3/pl unknown
- 2007-10-01 EA EA200900424A patent/EA018836B1/ru not_active IP Right Cessation
- 2007-10-01 US US12/444,130 patent/US8450464B2/en active Active
- 2007-10-01 HU HUE07867192A patent/HUE027165T2/en unknown
- 2007-10-01 LT LTEP12155398.6T patent/LT2486941T/lt unknown
- 2007-10-01 KR KR1020097008520A patent/KR101722261B1/ko active IP Right Grant
- 2007-10-01 KR KR1020177030856A patent/KR20170123712A/ko not_active Application Discontinuation
- 2007-10-01 MX MX2009003306A patent/MX2009003306A/es active IP Right Grant
- 2007-10-01 PT PT121553986T patent/PT2486941T/pt unknown
- 2007-10-02 CL CL200702835A patent/CL2007002835A1/es unknown
-
2009
- 2009-03-26 IL IL197831A patent/IL197831A/en active IP Right Grant
- 2009-03-30 NO NO20091283A patent/NO345287B1/no unknown
- 2009-04-01 ZA ZA2009/02256A patent/ZA200902256B/en unknown
- 2009-12-01 HK HK09111264.7A patent/HK1131904A1/xx unknown
-
2013
- 2013-05-23 US US13/900,791 patent/US10106615B2/en active Active
- 2013-07-24 JP JP2013153626A patent/JP6097650B2/ja active Active
-
2015
- 2015-12-09 CY CY20151101127T patent/CY1117036T1/el unknown
-
2016
- 2016-01-28 JP JP2016014621A patent/JP6496673B2/ja active Active
-
2017
- 2017-06-13 CY CY20171100625T patent/CY1118949T1/el unknown
-
2018
- 2018-04-26 AR ARP180101084A patent/AR113225A2/es unknown
- 2018-10-12 US US16/159,306 patent/US11312777B2/en active Active
- 2018-11-02 JP JP2018207100A patent/JP2019054798A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20091283L (no) | Humane antistoffer som binder CXCR4 og anvendelser derav | |
NO20081987L (no) | Humane, monoklonale antistoffer mot CD70 | |
NO20092285L (no) | Humane, monoklonale antistoffer til BTLA og fremgangsmater for anvendelse | |
NO20083062L (no) | Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1 | |
NO20082559L (no) | Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer | |
NO20083053L (no) | Humane monoklonale antistoffer mot O8E | |
NO20073797L (no) | Humane monoklonale antistoffer mot prostata spesifikt membran antigen (PSMA) | |
NO20064866L (no) | IRTA-5 antistoffer og deres anvendelse | |
MX2009005776A (es) | Anticuerpos humanos que se enlazan al cd 22 y sus usos. | |
EA200800229A1 (ru) | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) | |
MX2010005830A (es) | Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo. | |
MX2010000537A (es) | Anticuerpos monoclonales contra glipicano-3. | |
MY150246A (en) | Alpha 5 - beta 1 antibodies and their uses | |
MX2009006277A (es) | Anticuerpos humanos que se enlazan a cd70 y usos de los mismos. | |
NO20080362L (no) | CD19-antistoffer og deres anvendelser | |
CY1119539T1 (el) | Πληρως ανθρωπινα αντισωματα ειδικα για to cadμ1 | |
EA201000238A1 (ru) | Антигенсвязывающие белки для il-18 рецептора и их применение | |
EA201101516A1 (ru) | Антитела, специфические для кадгерина-17 | |
WO2006076691A3 (en) | Irta-2 antibodies and their uses | |
WO2006116192A3 (en) | Irta-1 antibodies and their uses | |
CY1113958T1 (el) | Ανθρωπινα μονοκλωνικα αντισωματα σε φουκοζυλ-gμ1 και μεθοδοι για τη χρηση αντι-φουκοζυλ-gμ1 | |
EA202190387A1 (ru) | Антитело к cd38 человека и его применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: MEDAREX LLC, US |
|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: E.R. SQUIBB & SONS, US |